Mechanisms and clinical implications of renal drug excretion

被引:89
作者
Masereeuw, R [1 ]
Russel, FGM [1 ]
机构
[1] Univ Med Ctr Nijmegen, Dept Pharmacol & Toxicol 233, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1081/DMR-120000654
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The body defends itself against potentially harmful compounds like drugs, toxic compounds, and their metabolites by elimination, in which the kidney plays an important role. Renal clearance is used to determine renal elimination mechanisms of a drug, which is the result of glomerular filtration, active tubular secretion and reabsorption. The renal proximal tubule is the primary site of carrier-mediated transport from blood to urine. Renal secretory mechanisms exists for, anionic compounds and organic cations. Both systems comprises several transport proteins, and knowledge of the molecular identity of these transporters and their substrate specificity has increased considerably in the past decade. Due to overlapping specificities of the transport proteins, drug interactions at the level of tubular secretion is an event that may occur in clinical situation. This review describes the different processes that determine renal drug handling, the techniques that have been developed to attain more insight in the various aspects of drug excretion, the functional characteristics of the individual transport proteins, and finally the implications of drug interactions in a clinical perspective.
引用
收藏
页码:299 / 351
页数:53
相关论文
共 395 条
  • [1] Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2
    Abe, T
    Kakyo, M
    Sakagami, H
    Tokui, T
    Nishio, T
    Tanemoto, M
    Nomura, H
    Hebert, SC
    Matsuno, S
    Kondo, H
    Yawo, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (35) : 22395 - 22401
  • [2] THE EFFECT OF FAMOTIDINE ON RENAL-FUNCTION IN PATIENTS WITH RENAL-INSUFFICIENCY
    ABRAHAM, PA
    OPSAHL, JA
    HALSTENSON, CE
    CHREMOS, AN
    MATZKE, GR
    KEANE, WF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (03) : 385 - 389
  • [3] Abu-Zahra TN, 2000, DRUG METAB DISPOS, V28, P801
  • [4] Akhteruzzaman S, 1999, J PHARMACOL EXP THER, V288, P575
  • [5] Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump
    Akita, H
    Suzuki, H
    Ito, K
    Kinoshita, S
    Sato, N
    Takikawa, H
    Sugiyama, Y
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1511 (01): : 7 - 16
  • [6] Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847
  • [7] Bach PH, 1990, J BIOPHARM SCI, V1, P277
  • [8] Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir
    Balimane, PV
    Tamai, I
    Guo, AL
    Nakanishi, T
    Kitada, H
    Leibach, FH
    Tsuji, A
    Sinko, PJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (02) : 246 - 251
  • [9] BARRETT BJ, 1994, J AM SOC NEPHROL, V5, P125
  • [10] THE EFFECTS OF INDOMETHACIN AND NAPROXEN ON ZIDOVUDINE PHARMACOKINETICS
    BARRY, M
    HOWE, J
    BACK, D
    BRECKENRIDGE, A
    BRETTLE, R
    MITCHELL, R
    BEECHING, NJ
    NYE, FJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (01) : 82 - 85